September 27, 2021, Shanghai, China – Luye Pharma Group today announced that Dulaglutide Injection (BA5101) developed in-house by Boan Biotech, a subsidiary of the Group, has obtained approval f...
September 26, 2021, Boston, USA - Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific anti...
Boan Biotech has announced significant progress with LY-CovMab, a neutralizing antibody independently developedfor the treatment of COVID-19. LY-CovMab has been preliminarily validated for effectively...
Luye Pharma Group today announced that Boyounuo (Bevacizumab Injection), an oncology biologic developed in-house by its subsidiary Boan Biotech, has been approved by China’s National Medical Pro...
Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) in Antibody Therapeutic...
博优诺®(Bevacizumab Injection), an anticancer drug developed by Boan Biotech, a subsidiary of Luye Pharma Group, was launched in China on June 5, 2021. The first product from Boan Biotech’s pipe...
Luye Pharma Group announced today that its holding subsidiary, Boan Biotech, has signed an agreement with AstraZeneca China regarding the promotion rights to the anticancer drug 博优诺® (Bevacizumab I...
Boan Biotech，a holding subsidiary of Luye Pharma Group, announced that its biopharmaceutical drug 博优诺®(Bevacizumab Injection) has received marketing authorization from China’s National Medic...
Luye Pharma Group today announced that Nivolumab injection (LY01015) developed by the Group's holding subsidiary Boan Biotech, has obtained the approval from the China’s National Medical Pro...
Luye Pharma Group today announced that the phase I clinical trial for LY-CovMab, an innovative antibody for the treatment of COVID-19, has been completed in China, with good results in safety and tole...
39 Keji Avenue, hi tech Zone, Yantai City, Shandong Province
（86）0535-4379111
zhaohongliu@luye.com
Follow me
